Key result
Therapeutic apheresis effectively reduces plasma Lp(a) concentrations in patients with progressive coronary heart disease and Lp(a) levels >50 mg/dL despite maximal drug therapy.
Why the study?
Does therapeutic apheresis reduce plasma Lp(a) concentration in patients with progressive coronary heart disease and elevated Lp(a)?
Does therapeutic apheresis reduce plasma Lp(a) concentration in patients with progressive coronary heart disease and elevated Lp(a)?
Therapeutic apheresis is highlighted as the most effective method to reduce plasma Lp(a) in high-risk patients with progressive coronary heart disease despite maximal drug therapy.
Lipoprotein (a) (Lp (a)) increases global cardiovascular risk, especially when LDL cholesterol is concomitantly elevated. Epidemiologic data show that Lp (a) concentration in plasma can be used to predict the risk of early atherogenesis in a dose-dependent manner and late stages of atherosclerosis are accelerated by elevated Lp (a). Therapeutic means to lower Lp (a) are limited. The most effective method to reduce plasma Lp (a) concentration significantly is therapeutic apheresis. Because apheresis is laborious and expensive, patients considered for this procedure should suffer from high Lp (a) concentrations, well beyond 50 mg/dL, and have manifested and progressive coronary heart disease despite maximal drug therapy. Experimental data and therapeutic results will be discussed in the present paper.
No takes yet. Share an insight, caveat, or question.
Christiane Keller (2007) conducted a review in Coronary Heart Disease with Elevated Lp(a). Therapeutic apheresis was evaluated. Therapeutic apheresis effectively reduces plasma Lp(a) concentrations in patients with progressive coronary heart disease and Lp(a) levels >50 mg/dL despite maximal drug therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: